Growth hormone-releasing hormone analogs: chemistry and pharmacology — VialBase Research

Summary

Review of GHRH analog chemistry and pharmacology, with focus on modifications that improve stability and extend half-life. Covers the development of CJC-1295 and the Drug Affinity Complex (DAC) technology that enables once-weekly dosing through reversible albumin binding.

Key Findings

• GHRH analogs like CJC-1295 stimulate GH release while preserving natural pulsatility
• DAC (Drug Affinity Complex) modification enables covalent albumin binding, extending half-life
• Pulsatile GH release pattern maintained — unlike flat exogenous GH administration
• CJC-1295 stimulates GH at the pituitary level, preserving negative feedback loops
• Modified amino acid sequence improves resistance to DPP-IV degradation
• Represents an alternative to exogenous GH replacement with potentially better safety profile

Methodology

Narrative review covering GHRH peptide chemistry, structure-activity relationships, pharmacokinetic modifications, and clinical pharmacology data for various GHRH analogs including CJC-1295.

Limitations

• Review focused on pharmacology — limited clinical outcome data
• DAC technology is specific to the DAC formulation (not “no-DAC” versions)
• Long-term safety of sustained GH/IGF-1 elevation not addressed
• Theoretical advantages over exogenous GH not validated in comparative trials
• Commercial development was discontinued after adverse events in clinical trials

Relevance to Content

Essential for content explaining why CJC-1295 is preferred over exogenous GH in the peptide space. The “preserving pulsatility” argument is a key differentiator. Also important context: the commercial (DAC) version had clinical trial adverse events — content should note the distinction between clinical-grade DAC and “no-DAC” versions used in practice.

See Also

• Parent compound: CJC-1295
• Sermorelin
• Tesamorelin